Aim: The aim of this study was to evaluate tacrolimus population pharmacokinetics and investigate factors that explain tacrolimus variability in adult heart transplant patients. Methods: A total of 707 tacrolimus concentrations from 107 adult heart transplant patients were included in model development. The effects of demographic, clinical factors and CYP3A5 genotype on tacrolimus clearance were evaluated using a nonlinear mixed-effects modeling. 24 patients with 106 tacrolimus concentrations were used for external validation. Results: The pharmacokinetic data were adequately described by a one-compartment model with first-order absorption and elimination. The estimated apparent clearance and volume of distribution of tacrolimus were 13.7 l/h and 791 l, respectively. Tacrolimus apparent clearance was significantly reduced in CYP3A5 nonexpressers (CYP3A5*3/*3), concomitant with azole antifungal drugs and Wuzhi capsule (WZ). A predictive performance was further confirmed in an external validation by Bayesian estimation. Recommended dose regimens were obtained by simulations based on the established model. Conclusion: This is the first population pharmacokinetic study conducted in Chinese heart transplant recipients. These findings are of great importance with regards to tacrolimus dose optimization in heart transplantation patients.
[1]Huazhong Univ Sci & Technol, Union Hosp, Dept Pharm, Tongji Med Coll, 1277 Jie Fang Rd, Wuhan 430022, Hubei, Peoples R China;
[2]Huazhong Univ Sci & Technol, Union Hosp, Dept Cardiovasc Surg, Tongji Med Coll, 1277 Jie Fang Rd, Wuhan 430022, Hubei, Peoples R China;
[3]Fudan Univ, Huashan Hosp, Inst Antibiot, 12 Middle Urumqi Rd, Shanghai 200040, Peoples R China
(8.0+极速模式)